View Future GrowthItaconix 과거 순이익 실적과거 기준 점검 0/6Itaconix 의 수입은 연평균 -6.3%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 4.4%의 비율로 감소했습니다. 매출은 연평균 22.6%의 비율로 증가해 왔습니다.핵심 정보-6.34%순이익 성장률6.66%주당순이익(EPS) 성장률Chemicals 산업 성장률12.41%매출 성장률22.57%자기자본이익률-16.76%순이익률-13.14%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트공시 • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026공시 • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025공시 • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025공시 • Sep 02Itaconix plc to Report First Half, 2024 Results on Sep 10, 2024Itaconix plc announced that they will report first half, 2024 results on Sep 10, 2024Reported Earnings • Apr 16Full year 2023 earnings released: US$0.12 loss per share (vs US$0.28 loss in FY 2022)Full year 2023 results: US$0.12 loss per share (improved from US$0.28 loss in FY 2022). Revenue: US$7.87m (up 41% from FY 2022). Net loss: US$1.54m (loss narrowed 38% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.공시 • Apr 08Itaconix plc to Report Fiscal Year 2023 Results on Apr 15, 2024Itaconix plc announced that they will report fiscal year 2023 results on Apr 15, 2024모든 업데이트 보기Recent updates공시 • Mar 24Itaconix plc, Annual General Meeting, May 14, 2026Itaconix plc, Annual General Meeting, May 14, 2026. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom공시 • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026공시 • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025공시 • Jul 02Itaconix plc Announces the Commercial Product Launch of BIO*AsterixItaconix plc announced the commercial product launch of BIOAsterix®?, a new line of plant-based functional building blocks for polymeric binders used in paints, coatings, and adhesives. The BIOAsterix products are specialty derivatives of itaconic acid that can fully or partially replace fossil-based acrylate, methacrylate, or styrene monomers in a wide range of resins and composites. The initial BIOAsterix offering consists of three products, including one new patented monomer, which are positioned as safer and more sustainable alternatives in the $2.6 billion market for butyl acrylates in Europe and North America. The Company plans to offer an extensive and comprehensive line of itaconate alternatives by adding additional proprietary and non-proprietary products to the BIOAsterix catalog in the future. Initial ecommerce customers are expected to come from North American academic and industry laboratories that are developing paths for safer and more sustainable polymers. The Company developed specialty itaconate derivatives that represent the beginning of a long-term growth initiative and future revenue opportunity for Itaconix. Commercial efforts over the last few years focused on specific usage with a limited number of potential customers. This new commercial product launch and use of ecommerce are expected to generate broader opportunities within the large and diverse paints and coatings segment of the acrylic acid market.공시 • May 05Itaconix plc, Annual General Meeting, May 08, 2025Itaconix plc, Annual General Meeting, May 08, 2025. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom공시 • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025공시 • Oct 16Itaconix plc Announces Launch of the Itaconix SPARX ProgramItaconix plc announced the launch of its SPARX program - a new collaborative initiative to increase the value and reduce the time-to-market for safer, better performing, and more sustainable home and personal care products. Itaconix developed the SPARX program in response to brands seeking new innovations to meet consumer desires for affordable products that perform better and are better for the world. As an extension of its existing formulated solutions work, the Company sees opportunities in a series of home and personal care product categories for new offerings that deliver excellent performance while using safer ingredients, more sustainable materials, less chemicals, and less plastic. The SPARX program will integrate the efforts of Itaconix and other advanced specialty ingredient companies with innovative end-product manufacturers and purpose-driven brands to speed the introduction of new generations of consumer products. The program has a goal for brands to introduce at least 10 new products by the end of 2025. The Company expects to announce SPARX collaborations with ingredient suppliers, contract manufacturers, and brands in the coming months towards achieving this goal. SPARX is being introduced by Itaconix at the annual SEPAWA® CONGRESS being held in Berlin (16-18 October). SEPAWA® is one of the most influential annual gatherings within the European and North American home detergent and cleaning industry.New Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€21.4m market cap, or US$23.7m).New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (€23.5m market cap, or US$26.1m).공시 • Sep 02Itaconix plc to Report First Half, 2024 Results on Sep 10, 2024Itaconix plc announced that they will report first half, 2024 results on Sep 10, 2024공시 • Jul 16Itaconix plc Reiterates Earnings Guidance for the First Six Months of 2024Itaconix plc reiterated earnings guidance for the first six months of 2024. For the months, the company expected its revenue expectations of $6 million to $6.5 million and gross profit margin expectations of 36% for Fiscal Year 2024.공시 • Apr 30Itaconix plc Launches Two New Plant-Based Performance Ingredients for Household Detergents and CleanersItaconix plc announced the launch of two new ingredients for improving the performance of household detergent formulations. The new products represent major advances in phosphate replacement with new multi-functional performance from plant-based materials that are safe for the environment. Itaconix®? TSI®? 422 is the latest and most advanced addition to Itaconix's revolutionary line of multi-functional ingredients for eliminating the detrimental effects of hard water in detergent and industrial applications. Itaconix TSI 422 extends the performance advantages of the Itaconix TSI 322, particularly in dishwashing detergents. Major benefits include better scale inhibition and more compact dosing while maintaining high plant-based content. Itaconix®? ONZ™? 405 is a new powder version of Itaconix's innovative line of liquid plant-based ingredients that add both fast-acting odor neutralization and excellent scale inhibition to detergents and cleaners. The new powder form extends the potential for new performance claims into important consumer product categories such as powder laundry additives and plastic-free detergent concentrates.공시 • Apr 17Itaconix plc Provides Revenue Guidance for the Year 2024Itaconix plc provided revenue guidance for the year 2024. For the period, Company expects lower revenues due to not reaching satisfactory commercial terms with an existing North American detergent merchandizing customer following extensive negotiations.공시 • Apr 16Itaconix plc, Annual General Meeting, May 20, 2024Itaconix plc, Annual General Meeting, May 20, 2024, at 13:00 Coordinated Universal Time. Location: Fieldfisher LLP, 9th Floor, Riverbank House, 2 Swan Lane, London United KingdomReported Earnings • Apr 16Full year 2023 earnings released: US$0.12 loss per share (vs US$0.28 loss in FY 2022)Full year 2023 results: US$0.12 loss per share (improved from US$0.28 loss in FY 2022). Revenue: US$7.87m (up 41% from FY 2022). Net loss: US$1.54m (loss narrowed 38% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.공시 • Apr 08Itaconix plc to Report Fiscal Year 2023 Results on Apr 15, 2024Itaconix plc announced that they will report fiscal year 2023 results on Apr 15, 2024New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Market cap is less than US$100m (€41.3m market cap, or US$44.6m).공시 • Feb 09Itaconix plc Appoints Jonathan Brooks as Independent Non-Executive DirectorItaconix plc announced the appointment of Jonathan Brooks to the Board as an independent Non-Executive Director. Jonathan is recently retired from the European law firm Fieldfisher LLP where he was a Partner in its highly regarded Equity Capital Markets practice. Prior to joining Fieldfisher, he was a Partner and Head of the Capital Markets Group at Maclay Murray & Spens LLP, having qualified as a solicitor and subsequently becoming a Partner at Boodle Hatfield LLP. With over 35 years of experience, Jonathan has acted for clients in a diverse range of industries, including technology, materials, healthcare, natural resources, renewable energy, and financial services. His experience extends across key corporate growth activities, serving as a valued advisor in numerous IPOs, fundraisings, and venture capital investments. He has managed transactions and advised on legal, regulatory, corporate governance and sustainability matters for a range of high-growth companies in the global equity capital markets.공시 • Dec 07Itaconix plc Provides Earning Guidance for the Year 2023 , Fiscal Year 2024 and for Fiscal Year 2025Itaconix plc provided earning guidance for the Year 2023, Fiscal Year 2024 and for Fiscal year 2025. For the year 2023 company expects revenues to be at least $7.7 Million, with Fiscal year 2023 earnings expected to be in line with current market expectations.For the Fiscal year 2024, revenue expectations are revised to $9.5 Million or more For the fiscal year 2025, company expects revenue of $12.5 Million or more, with no change to earnings expectations.Reported Earnings • Sep 17First half 2023 earnings released: US$0.054 loss per share (vs US$0.13 loss in 1H 2022)First half 2023 results: US$0.054 loss per share (improved from US$0.13 loss in 1H 2022). Revenue: US$4.03m (up 32% from 1H 2022). Net loss: US$694.0k (loss narrowed 38% from 1H 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Chemicals industry in Germany.공시 • Sep 05Itaconix plc to Report First Half, 2023 Results on Sep 12, 2023Itaconix plc announced that they will report first half, 2023 results on Sep 12, 2023New Risk • Aug 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 28% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$278k free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-US$775k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$708k net loss in 3 years). Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (€30.5m market cap, or US$33.0m).New Risk • Jun 12New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$775k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$278k free cash flow). Negative equity (-US$775k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$697k net loss in 3 years). Share price has been volatile over the past 3 months (7.7% average weekly change). Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (€36.2m market cap, or US$39.0m).Reported Earnings • Jun 05Full year 2022 earnings released: US$0.50 loss per share (vs US$0.001 loss in FY 2021)Full year 2022 results: US$0.50 loss per share (further deteriorated from US$0.001 loss in FY 2021). Revenue: US$5.60m (up 116% from FY 2021). Net loss: US$2.46m (loss widened 441% from FY 2021). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany.공시 • May 25+ 1 more updateItaconix plc, Annual General Meeting, Jun 28, 2023Itaconix plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: At the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London London United Kingdom공시 • Feb 03+ 1 more updateItaconix plc, Annual General Meeting, Feb 22, 2023Itaconix plc, Annual General Meeting, Feb 22, 2023, at 11:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP at Riverbank House, 2 Swan Lane :London United Kingdom Agenda: To allot Ordinary Shares and to grant rights to subscribe for or to convert any security into Ordinary Shares up to an aggregate nominal amount of £8,203,187.39; to grant the Directors authority to allot equity securities under the authority given by resolution 1 for cash free of the statutory pre-emption rights which would otherwise apply, such authority to be limited; to consider Directors be authorised in addition to any authority granted under resolution 2 to allot equity securities for cash free of statutory pre-emption rights.공시 • Jan 05Itaconix plc Announces Board ChangesItaconix plc announced changes to the Board. Paul LeBlanc is appointed to the Board as an independent Non-Executive Director and Chair of the Audit Committee with effect from January 5, 2023. He is Chief Financial Officer and Treasurer of Bemis Associates Inc, a global manufacturer of specialty films and adhesives for the apparel and industrial markets. He joined Bemis in 1999 as Controller and assumed increasing levels of responsibility during Bemis' rapid growth into a global manufacturer, including overseeing the acquisition and integration of operations in Europe and Asia. He earned his Bachelor of Science in Accounting from Thomas College and his Master of Business Administration from University of Massachusetts, Dartmouth. In addition, Dr. Peter Nieuwenhuizen, the Company's Non-Executive Interim Chair, who joined the Board in July 2022, now takes the role of Non-Executive Chair on a permanent basis and with effect from January 5, 2023. The Board now comprises Dr. Peter Nieuwenhuizen (Non-Executive Chair), Paul LeBlanc (Non-Executive Director), John R. Shaw (Chief Executive Officer), and Laura Denner (Chief Financial Officer).Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering Itaconix expects the company to break even for the first time. New forecast suggests the company will make a profit of US$199.5k in 2024. Average annual earnings growth of 77% is required to achieve expected profit on schedule.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 15First half 2022 earnings released: US$0.003 loss per share (vs US$0 in 1H 2021)First half 2022 results: US$0.003 loss per share (further deteriorated from US$0 in 1H 2021). Revenue: US$3.06m (up 124% from 1H 2021). Net loss: US$1.12m (loss widened US$941.0k from 1H 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 1.2% growth forecast for the Chemicals industry in Germany.공시 • Sep 14Itaconix plc Provides Earnings Guidance for the Full Year 2022Itaconix plc provided earnings guidance for the full year 2022. For the year, the company remains on course to deliver revenues ahead of current market expectations based on progress in commercial volumes and success in passing on increases in direct costs.공시 • Sep 07Itaconix plc to Report First Half, 2022 Results on Sep 14, 2022Itaconix plc announced that they will report first half, 2022 results on Sep 14, 2022Board Change • Jul 24Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Jul 20Itaconix plc Appoints Laura Denner as Executive DirectorLaura Denner is appointed to the Board of Itaconix as an Executive Director effective July 20, 2022. Laura has assumed increasing finance, accounting, and operations responsibilities since joining Itaconix Corporation in 2013. She has served as the Company's Chief Financial Officer since 2018. Previously, she worked as Audit Manager for Feeley & Driscoll (now within BDO). Sheholds a Master of Science degree in accounting from Boston College and a Bachelor of Arts degree in accounting and international studies from Bryant University. The Board now comprises Dr. Peter Nieuwenhuizen (Non-Executive Interim Chair), John R. Shaw (Chief Executive Officer), and Laura Denner (Chief Financial Officer).공시 • Jul 05Itaconix plc Announces Directorate ChangeItaconix announced changes to the Board. Dr. James Barber has stepped down as Chair and Non-Executive Director of the Board with immediate effect. Dr. Barber served as a Non-Executive Director of Itaconix plc since 2016 and Chair since 2018. He also served as a Director of Itaconix Corporation from 2012 to 2016. Dr. Peter Nieuwenhuizen isappointed to the Board as a Non-Executive Director and Interim Chair with immediate effect. He is a Founding Partner of the European Circular Bioeconomy Fund ("ECBF"), a €300 million venture capitalfund dedicated to the circular bioeconomy. He serves as Chair of the Green Chemistry and Commerce Council, as Boardmember of PeelPioneers B.V. and In Ovo Holding B.V., and as an advisor to Solugen LLC and to Cosun (Coöperatie Koninklijke Cosun U.A.). Prior to co-founding ECBF, Peter was CTO & Corporate Director RD&I & Sustainability for AkzoNobel Specialty Chemicals (now Nouryon B.V.) and CTO of Enerkem Inc.He earned his Ph.D. in Chemistry from Leiden University. As a result, the Board now comprises Dr. Nieuwenhuizen (Non-Executive Interim Chairman) and John R. Shaw (Chief Executive Officer). The Company is actively working on further Board appointments, to include recruitment of an additional independent non executive director.Breakeven Date Change • Jun 10Forecast to breakeven in 2024The analyst covering Itaconix expects the company to break even for the first time. New forecast suggests the company will make a profit of US$199.5k in 2024. Average annual earnings growth of 46% is required to achieve expected profit on schedule.Reported Earnings • Jun 09Full year 2021 earnings released: US$0.001 loss per share (vs US$0.005 loss in FY 2020)Full year 2021 results: US$0.001 loss per share (up from US$0.005 loss in FY 2020). Revenue: US$2.60m (down 21% from FY 2020). Net loss: US$455.0k (loss narrowed 72% from FY 2020). Over the next year, revenue is forecast to grow 81%, compared to a 6.5% growth forecast for the industry in Germany.Board Change • May 31High number of new directorsIndependent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022.공시 • May 27+ 1 more updateItaconix plc, Annual General Meeting, Jul 01, 2022Itaconix plc, Annual General Meeting, Jul 01, 2022, at 12:00 Coordinated Universal Time. Location: Fieldfisher LLP, Riverbank House, 2 Swan Lane London United Kingdom공시 • May 08Itaconix plc announced that it has received $0.06525 million in fundingOn May 6, 2022, Itaconix Plc closed the transaction. The transaction included participation from 2 investors.Board Change • Apr 27High number of new directorsIndependent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022.공시 • Apr 19Itaconix plc Announces Board ChangesItaconix plc announced that Dr. Bryan Dobson will retire as an independent non-executive director, to be replaced by Charlean Gmunder, with immediate effect. Ms. Gmunder is chief operating officer of Blue Apron Holdings Inc.Board Change • Mar 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. CEO & Director John Shaw was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Feb 10Itaconix plc Announces Supplied Product for the First Production Trial Using the Company's Plant-Based Superabsorbent, Velafresh® Sap80Itaconix announced that it has supplied product for the first production trial using the Company's plant-based superabsorbent, VELAFRESH® SAP80. VELAFRESH® SAP80 is being trialed by a leading supplier to companies that produce baby diapers, feminine hygiene products, adult diapers, and industrial absorption products. This follows the Company's production trials for VELAFRESH® SAP80 in 2021. If the prospective customer's trials are favourable, potential Itaconix revenues are expected to start in 2023. Increasing consumer interest in more sustainable hygiene products is generating new addressable markets for Itaconix's plant-based polymers. The worldwide market for superabsorbent polymers (SAPs) was estimated at $9.0 billion in 2020 and is supplied almost entirely by fossil-based polymers due to the higher cost or lower performance of current plant-based polymers. The Company believes VELAFRESH® SAP80 offers a superior level of performance, cost, and availability for brands and consumers that are seeking more sustainable hygiene products.공시 • Feb 03Itaconix plc Extends its Technology Platform into Potential Uses in Composite Materials and Files New Patent to Protect Innovative Intellectual PropertyItaconix plc announced that the Company is extending the Itaconix technology platform into potential uses in composite materials and has filed a new patent to protect innovative intellectual property for expected applications in this new area. The extension of the Itaconix technology platform is part of the Company's efforts to engage with potential customers to identify sizable unmet needs that Itaconix can address with plant-based solutions. Market and materials research led by Dr. Yvon Durant, Itaconix's CTO, has created a path to making certain composite materials that may allow a safer process to produce products that also have higher plant-based content. If granted, the patent will protect a new family of intellectual property for Itaconix. The review process for the filing is expected to take at least two years, and there is no guarantee that the patent will be granted. Product research based on this patent filing will now enter the next stage of commercial development. Key milestones for 2022 are to complete initial environmental and safety studies and to engage in commercial discussions with market collaborators.공시 • Jan 26Itaconix plc Provides Revenue Guidance for the Year Ended 31 December 2021Itaconix plc provided revenue guidance for the year ended 31 December 2021. The company expects to report results in line with market expectations with revenues of $2.6 million.공시 • Dec 22Itaconix plc Provides Update on Production ResumptionItaconix plc provide an update to the 4 November 2021 announcement regarding the temporary interruption to operations due to water damage. The Company was successful with interim measures to resume production in the middle of November, with permanent repairs scheduled to be completed in the coming weeks. Itaconix has met and expects to continue to meet all customer orders. The Company is working closely with one large customer on minor delivery delays that will not impact the customer's operating needs. Itaconix has filed a claim with the relevant insurers to cover the costs of both property damage and operational costs incurred.Board Change • Dec 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. CEO & Director John Shaw was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Jun 09Itaconix plc has completed a Follow-on Equity Offering in the amount of £1.100025 million.Itaconix plc has completed a Follow-on Equity Offering in the amount of £1.100025 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,091,115 Price\Range: £0.121 Discount Per Security: £0.032 Transaction Features: Subsequent Direct Listing매출 및 비용 세부 내역Itaconix가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:18G0 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 2510-14030 Sep 2510-14030 Jun 259-14031 Mar 258-24031 Dec 247-24030 Sep 247-24030 Jun 247-24031 Mar 247-24031 Dec 238-24030 Sep 237-24030 Jun 237-24031 Mar 236-24031 Dec 226-24030 Sep 225-23030 Jun 224-13031 Mar 223-13031 Dec 21303030 Sep 213-13030 Jun 214-13031 Mar 213-13031 Dec 203-22030 Sep 203-13030 Jun 20203031 Mar 202-13031 Dec 191-13030 Sep 191-54030 Jun 191-84031 Mar 191-95031 Dec 181-106030 Jun 181-146131 Mar 181-156231 Dec 171-146130 Jun 171-75231 Mar 171-65231 Dec 160-64230 Jun 16-1-42231 Mar 160-22231 Dec 150-11230 Sep 152-33330 Jun 152-323양질의 수익: 18G0 은(는) 현재 수익성이 없습니다.이익 마진 증가: 18G0는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 18G0은 수익성이 없으며 지난 5년 동안 손실이 연평균 6.3% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 18G0의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 18G0은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(-13.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 18G0는 현재 수익성이 없으므로 자본 수익률이 음수(-16.76%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 17:11종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Itaconix plc는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Alexander BrooksCanaccord Genuity
공시 • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026
공시 • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025
공시 • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025
공시 • Sep 02Itaconix plc to Report First Half, 2024 Results on Sep 10, 2024Itaconix plc announced that they will report first half, 2024 results on Sep 10, 2024
Reported Earnings • Apr 16Full year 2023 earnings released: US$0.12 loss per share (vs US$0.28 loss in FY 2022)Full year 2023 results: US$0.12 loss per share (improved from US$0.28 loss in FY 2022). Revenue: US$7.87m (up 41% from FY 2022). Net loss: US$1.54m (loss narrowed 38% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.
공시 • Apr 08Itaconix plc to Report Fiscal Year 2023 Results on Apr 15, 2024Itaconix plc announced that they will report fiscal year 2023 results on Apr 15, 2024
공시 • Mar 24Itaconix plc, Annual General Meeting, May 14, 2026Itaconix plc, Annual General Meeting, May 14, 2026. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
공시 • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026
공시 • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025
공시 • Jul 02Itaconix plc Announces the Commercial Product Launch of BIO*AsterixItaconix plc announced the commercial product launch of BIOAsterix®?, a new line of plant-based functional building blocks for polymeric binders used in paints, coatings, and adhesives. The BIOAsterix products are specialty derivatives of itaconic acid that can fully or partially replace fossil-based acrylate, methacrylate, or styrene monomers in a wide range of resins and composites. The initial BIOAsterix offering consists of three products, including one new patented monomer, which are positioned as safer and more sustainable alternatives in the $2.6 billion market for butyl acrylates in Europe and North America. The Company plans to offer an extensive and comprehensive line of itaconate alternatives by adding additional proprietary and non-proprietary products to the BIOAsterix catalog in the future. Initial ecommerce customers are expected to come from North American academic and industry laboratories that are developing paths for safer and more sustainable polymers. The Company developed specialty itaconate derivatives that represent the beginning of a long-term growth initiative and future revenue opportunity for Itaconix. Commercial efforts over the last few years focused on specific usage with a limited number of potential customers. This new commercial product launch and use of ecommerce are expected to generate broader opportunities within the large and diverse paints and coatings segment of the acrylic acid market.
공시 • May 05Itaconix plc, Annual General Meeting, May 08, 2025Itaconix plc, Annual General Meeting, May 08, 2025. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
공시 • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025
공시 • Oct 16Itaconix plc Announces Launch of the Itaconix SPARX ProgramItaconix plc announced the launch of its SPARX program - a new collaborative initiative to increase the value and reduce the time-to-market for safer, better performing, and more sustainable home and personal care products. Itaconix developed the SPARX program in response to brands seeking new innovations to meet consumer desires for affordable products that perform better and are better for the world. As an extension of its existing formulated solutions work, the Company sees opportunities in a series of home and personal care product categories for new offerings that deliver excellent performance while using safer ingredients, more sustainable materials, less chemicals, and less plastic. The SPARX program will integrate the efforts of Itaconix and other advanced specialty ingredient companies with innovative end-product manufacturers and purpose-driven brands to speed the introduction of new generations of consumer products. The program has a goal for brands to introduce at least 10 new products by the end of 2025. The Company expects to announce SPARX collaborations with ingredient suppliers, contract manufacturers, and brands in the coming months towards achieving this goal. SPARX is being introduced by Itaconix at the annual SEPAWA® CONGRESS being held in Berlin (16-18 October). SEPAWA® is one of the most influential annual gatherings within the European and North American home detergent and cleaning industry.
New Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€21.4m market cap, or US$23.7m).
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (€23.5m market cap, or US$26.1m).
공시 • Sep 02Itaconix plc to Report First Half, 2024 Results on Sep 10, 2024Itaconix plc announced that they will report first half, 2024 results on Sep 10, 2024
공시 • Jul 16Itaconix plc Reiterates Earnings Guidance for the First Six Months of 2024Itaconix plc reiterated earnings guidance for the first six months of 2024. For the months, the company expected its revenue expectations of $6 million to $6.5 million and gross profit margin expectations of 36% for Fiscal Year 2024.
공시 • Apr 30Itaconix plc Launches Two New Plant-Based Performance Ingredients for Household Detergents and CleanersItaconix plc announced the launch of two new ingredients for improving the performance of household detergent formulations. The new products represent major advances in phosphate replacement with new multi-functional performance from plant-based materials that are safe for the environment. Itaconix®? TSI®? 422 is the latest and most advanced addition to Itaconix's revolutionary line of multi-functional ingredients for eliminating the detrimental effects of hard water in detergent and industrial applications. Itaconix TSI 422 extends the performance advantages of the Itaconix TSI 322, particularly in dishwashing detergents. Major benefits include better scale inhibition and more compact dosing while maintaining high plant-based content. Itaconix®? ONZ™? 405 is a new powder version of Itaconix's innovative line of liquid plant-based ingredients that add both fast-acting odor neutralization and excellent scale inhibition to detergents and cleaners. The new powder form extends the potential for new performance claims into important consumer product categories such as powder laundry additives and plastic-free detergent concentrates.
공시 • Apr 17Itaconix plc Provides Revenue Guidance for the Year 2024Itaconix plc provided revenue guidance for the year 2024. For the period, Company expects lower revenues due to not reaching satisfactory commercial terms with an existing North American detergent merchandizing customer following extensive negotiations.
공시 • Apr 16Itaconix plc, Annual General Meeting, May 20, 2024Itaconix plc, Annual General Meeting, May 20, 2024, at 13:00 Coordinated Universal Time. Location: Fieldfisher LLP, 9th Floor, Riverbank House, 2 Swan Lane, London United Kingdom
Reported Earnings • Apr 16Full year 2023 earnings released: US$0.12 loss per share (vs US$0.28 loss in FY 2022)Full year 2023 results: US$0.12 loss per share (improved from US$0.28 loss in FY 2022). Revenue: US$7.87m (up 41% from FY 2022). Net loss: US$1.54m (loss narrowed 38% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.
공시 • Apr 08Itaconix plc to Report Fiscal Year 2023 Results on Apr 15, 2024Itaconix plc announced that they will report fiscal year 2023 results on Apr 15, 2024
New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Market cap is less than US$100m (€41.3m market cap, or US$44.6m).
공시 • Feb 09Itaconix plc Appoints Jonathan Brooks as Independent Non-Executive DirectorItaconix plc announced the appointment of Jonathan Brooks to the Board as an independent Non-Executive Director. Jonathan is recently retired from the European law firm Fieldfisher LLP where he was a Partner in its highly regarded Equity Capital Markets practice. Prior to joining Fieldfisher, he was a Partner and Head of the Capital Markets Group at Maclay Murray & Spens LLP, having qualified as a solicitor and subsequently becoming a Partner at Boodle Hatfield LLP. With over 35 years of experience, Jonathan has acted for clients in a diverse range of industries, including technology, materials, healthcare, natural resources, renewable energy, and financial services. His experience extends across key corporate growth activities, serving as a valued advisor in numerous IPOs, fundraisings, and venture capital investments. He has managed transactions and advised on legal, regulatory, corporate governance and sustainability matters for a range of high-growth companies in the global equity capital markets.
공시 • Dec 07Itaconix plc Provides Earning Guidance for the Year 2023 , Fiscal Year 2024 and for Fiscal Year 2025Itaconix plc provided earning guidance for the Year 2023, Fiscal Year 2024 and for Fiscal year 2025. For the year 2023 company expects revenues to be at least $7.7 Million, with Fiscal year 2023 earnings expected to be in line with current market expectations.For the Fiscal year 2024, revenue expectations are revised to $9.5 Million or more For the fiscal year 2025, company expects revenue of $12.5 Million or more, with no change to earnings expectations.
Reported Earnings • Sep 17First half 2023 earnings released: US$0.054 loss per share (vs US$0.13 loss in 1H 2022)First half 2023 results: US$0.054 loss per share (improved from US$0.13 loss in 1H 2022). Revenue: US$4.03m (up 32% from 1H 2022). Net loss: US$694.0k (loss narrowed 38% from 1H 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Chemicals industry in Germany.
공시 • Sep 05Itaconix plc to Report First Half, 2023 Results on Sep 12, 2023Itaconix plc announced that they will report first half, 2023 results on Sep 12, 2023
New Risk • Aug 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 28% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$278k free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-US$775k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$708k net loss in 3 years). Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (€30.5m market cap, or US$33.0m).
New Risk • Jun 12New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$775k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$278k free cash flow). Negative equity (-US$775k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$697k net loss in 3 years). Share price has been volatile over the past 3 months (7.7% average weekly change). Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (€36.2m market cap, or US$39.0m).
Reported Earnings • Jun 05Full year 2022 earnings released: US$0.50 loss per share (vs US$0.001 loss in FY 2021)Full year 2022 results: US$0.50 loss per share (further deteriorated from US$0.001 loss in FY 2021). Revenue: US$5.60m (up 116% from FY 2021). Net loss: US$2.46m (loss widened 441% from FY 2021). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany.
공시 • May 25+ 1 more updateItaconix plc, Annual General Meeting, Jun 28, 2023Itaconix plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: At the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London London United Kingdom
공시 • Feb 03+ 1 more updateItaconix plc, Annual General Meeting, Feb 22, 2023Itaconix plc, Annual General Meeting, Feb 22, 2023, at 11:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP at Riverbank House, 2 Swan Lane :London United Kingdom Agenda: To allot Ordinary Shares and to grant rights to subscribe for or to convert any security into Ordinary Shares up to an aggregate nominal amount of £8,203,187.39; to grant the Directors authority to allot equity securities under the authority given by resolution 1 for cash free of the statutory pre-emption rights which would otherwise apply, such authority to be limited; to consider Directors be authorised in addition to any authority granted under resolution 2 to allot equity securities for cash free of statutory pre-emption rights.
공시 • Jan 05Itaconix plc Announces Board ChangesItaconix plc announced changes to the Board. Paul LeBlanc is appointed to the Board as an independent Non-Executive Director and Chair of the Audit Committee with effect from January 5, 2023. He is Chief Financial Officer and Treasurer of Bemis Associates Inc, a global manufacturer of specialty films and adhesives for the apparel and industrial markets. He joined Bemis in 1999 as Controller and assumed increasing levels of responsibility during Bemis' rapid growth into a global manufacturer, including overseeing the acquisition and integration of operations in Europe and Asia. He earned his Bachelor of Science in Accounting from Thomas College and his Master of Business Administration from University of Massachusetts, Dartmouth. In addition, Dr. Peter Nieuwenhuizen, the Company's Non-Executive Interim Chair, who joined the Board in July 2022, now takes the role of Non-Executive Chair on a permanent basis and with effect from January 5, 2023. The Board now comprises Dr. Peter Nieuwenhuizen (Non-Executive Chair), Paul LeBlanc (Non-Executive Director), John R. Shaw (Chief Executive Officer), and Laura Denner (Chief Financial Officer).
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering Itaconix expects the company to break even for the first time. New forecast suggests the company will make a profit of US$199.5k in 2024. Average annual earnings growth of 77% is required to achieve expected profit on schedule.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 15First half 2022 earnings released: US$0.003 loss per share (vs US$0 in 1H 2021)First half 2022 results: US$0.003 loss per share (further deteriorated from US$0 in 1H 2021). Revenue: US$3.06m (up 124% from 1H 2021). Net loss: US$1.12m (loss widened US$941.0k from 1H 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 1.2% growth forecast for the Chemicals industry in Germany.
공시 • Sep 14Itaconix plc Provides Earnings Guidance for the Full Year 2022Itaconix plc provided earnings guidance for the full year 2022. For the year, the company remains on course to deliver revenues ahead of current market expectations based on progress in commercial volumes and success in passing on increases in direct costs.
공시 • Sep 07Itaconix plc to Report First Half, 2022 Results on Sep 14, 2022Itaconix plc announced that they will report first half, 2022 results on Sep 14, 2022
Board Change • Jul 24Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Jul 20Itaconix plc Appoints Laura Denner as Executive DirectorLaura Denner is appointed to the Board of Itaconix as an Executive Director effective July 20, 2022. Laura has assumed increasing finance, accounting, and operations responsibilities since joining Itaconix Corporation in 2013. She has served as the Company's Chief Financial Officer since 2018. Previously, she worked as Audit Manager for Feeley & Driscoll (now within BDO). Sheholds a Master of Science degree in accounting from Boston College and a Bachelor of Arts degree in accounting and international studies from Bryant University. The Board now comprises Dr. Peter Nieuwenhuizen (Non-Executive Interim Chair), John R. Shaw (Chief Executive Officer), and Laura Denner (Chief Financial Officer).
공시 • Jul 05Itaconix plc Announces Directorate ChangeItaconix announced changes to the Board. Dr. James Barber has stepped down as Chair and Non-Executive Director of the Board with immediate effect. Dr. Barber served as a Non-Executive Director of Itaconix plc since 2016 and Chair since 2018. He also served as a Director of Itaconix Corporation from 2012 to 2016. Dr. Peter Nieuwenhuizen isappointed to the Board as a Non-Executive Director and Interim Chair with immediate effect. He is a Founding Partner of the European Circular Bioeconomy Fund ("ECBF"), a €300 million venture capitalfund dedicated to the circular bioeconomy. He serves as Chair of the Green Chemistry and Commerce Council, as Boardmember of PeelPioneers B.V. and In Ovo Holding B.V., and as an advisor to Solugen LLC and to Cosun (Coöperatie Koninklijke Cosun U.A.). Prior to co-founding ECBF, Peter was CTO & Corporate Director RD&I & Sustainability for AkzoNobel Specialty Chemicals (now Nouryon B.V.) and CTO of Enerkem Inc.He earned his Ph.D. in Chemistry from Leiden University. As a result, the Board now comprises Dr. Nieuwenhuizen (Non-Executive Interim Chairman) and John R. Shaw (Chief Executive Officer). The Company is actively working on further Board appointments, to include recruitment of an additional independent non executive director.
Breakeven Date Change • Jun 10Forecast to breakeven in 2024The analyst covering Itaconix expects the company to break even for the first time. New forecast suggests the company will make a profit of US$199.5k in 2024. Average annual earnings growth of 46% is required to achieve expected profit on schedule.
Reported Earnings • Jun 09Full year 2021 earnings released: US$0.001 loss per share (vs US$0.005 loss in FY 2020)Full year 2021 results: US$0.001 loss per share (up from US$0.005 loss in FY 2020). Revenue: US$2.60m (down 21% from FY 2020). Net loss: US$455.0k (loss narrowed 72% from FY 2020). Over the next year, revenue is forecast to grow 81%, compared to a 6.5% growth forecast for the industry in Germany.
Board Change • May 31High number of new directorsIndependent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022.
공시 • May 27+ 1 more updateItaconix plc, Annual General Meeting, Jul 01, 2022Itaconix plc, Annual General Meeting, Jul 01, 2022, at 12:00 Coordinated Universal Time. Location: Fieldfisher LLP, Riverbank House, 2 Swan Lane London United Kingdom
공시 • May 08Itaconix plc announced that it has received $0.06525 million in fundingOn May 6, 2022, Itaconix Plc closed the transaction. The transaction included participation from 2 investors.
Board Change • Apr 27High number of new directorsIndependent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022.
공시 • Apr 19Itaconix plc Announces Board ChangesItaconix plc announced that Dr. Bryan Dobson will retire as an independent non-executive director, to be replaced by Charlean Gmunder, with immediate effect. Ms. Gmunder is chief operating officer of Blue Apron Holdings Inc.
Board Change • Mar 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. CEO & Director John Shaw was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Feb 10Itaconix plc Announces Supplied Product for the First Production Trial Using the Company's Plant-Based Superabsorbent, Velafresh® Sap80Itaconix announced that it has supplied product for the first production trial using the Company's plant-based superabsorbent, VELAFRESH® SAP80. VELAFRESH® SAP80 is being trialed by a leading supplier to companies that produce baby diapers, feminine hygiene products, adult diapers, and industrial absorption products. This follows the Company's production trials for VELAFRESH® SAP80 in 2021. If the prospective customer's trials are favourable, potential Itaconix revenues are expected to start in 2023. Increasing consumer interest in more sustainable hygiene products is generating new addressable markets for Itaconix's plant-based polymers. The worldwide market for superabsorbent polymers (SAPs) was estimated at $9.0 billion in 2020 and is supplied almost entirely by fossil-based polymers due to the higher cost or lower performance of current plant-based polymers. The Company believes VELAFRESH® SAP80 offers a superior level of performance, cost, and availability for brands and consumers that are seeking more sustainable hygiene products.
공시 • Feb 03Itaconix plc Extends its Technology Platform into Potential Uses in Composite Materials and Files New Patent to Protect Innovative Intellectual PropertyItaconix plc announced that the Company is extending the Itaconix technology platform into potential uses in composite materials and has filed a new patent to protect innovative intellectual property for expected applications in this new area. The extension of the Itaconix technology platform is part of the Company's efforts to engage with potential customers to identify sizable unmet needs that Itaconix can address with plant-based solutions. Market and materials research led by Dr. Yvon Durant, Itaconix's CTO, has created a path to making certain composite materials that may allow a safer process to produce products that also have higher plant-based content. If granted, the patent will protect a new family of intellectual property for Itaconix. The review process for the filing is expected to take at least two years, and there is no guarantee that the patent will be granted. Product research based on this patent filing will now enter the next stage of commercial development. Key milestones for 2022 are to complete initial environmental and safety studies and to engage in commercial discussions with market collaborators.
공시 • Jan 26Itaconix plc Provides Revenue Guidance for the Year Ended 31 December 2021Itaconix plc provided revenue guidance for the year ended 31 December 2021. The company expects to report results in line with market expectations with revenues of $2.6 million.
공시 • Dec 22Itaconix plc Provides Update on Production ResumptionItaconix plc provide an update to the 4 November 2021 announcement regarding the temporary interruption to operations due to water damage. The Company was successful with interim measures to resume production in the middle of November, with permanent repairs scheduled to be completed in the coming weeks. Itaconix has met and expects to continue to meet all customer orders. The Company is working closely with one large customer on minor delivery delays that will not impact the customer's operating needs. Itaconix has filed a claim with the relevant insurers to cover the costs of both property damage and operational costs incurred.
Board Change • Dec 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. CEO & Director John Shaw was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Jun 09Itaconix plc has completed a Follow-on Equity Offering in the amount of £1.100025 million.Itaconix plc has completed a Follow-on Equity Offering in the amount of £1.100025 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,091,115 Price\Range: £0.121 Discount Per Security: £0.032 Transaction Features: Subsequent Direct Listing